Compare AbbVie Inc (ABBV) vs GraniteShares 2x Long NVDA Daily ETF (NVDL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs GraniteShares 2x Long NVDA Daily ETF — how do they compare? AbbVie Inc trades at $251.5 (market cap $439.59B), while GraniteShares 2x Long NVDA Daily ETF trades at $36.58. The key difference: AbbVie Inc pays a 2.78% dividend while GraniteShares 2x Long NVDA Daily ETF pays none, and AbbVie Inc is trading nearer its 52-week high, GraniteShares 2x Long NVDA Daily ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | NVDL | |
|---|---|---|
Market Cap | $439.59B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $263.58 | $43.02 |
52-Week Low | $197.38 | $21.76 |
Enterprise Value | $503.84B | — |
Dividend Yield | 2.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.94, up 0.82% today, with a bullish technical signal and strong analyst consensus. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $3.87. Revenue growth is robust, projected at $64.4B for 2026, driven by immunology drugs Skyrizi and Rinvoq offsetting Humira declines. The company maintains a solid dividend, with a recent $1.73 payout announced for H2-2026.
The outlook for ABBV is positive, supported by earnings momentum and a diversified pipeline, though high valuation ratios and patent cliffs in the 2030s present risks. Institutional ownership is growing, reflecting confidence in the company's strategic direction. Investors should weigh the strong growth prospects against the elevated P/E of 70.27 and significant long-term debt of $60.34B.
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $36.40, up 5.94% with a bullish technical signal from moving averages. The ETF provides leveraged exposure to NVIDIA's AI-driven growth, though recent performance has trailed NVDA's gains. Technical indicators show mixed signals with overbought RSI levels but strong trend momentum from ADX readings.
The outlook remains tied to NVIDIA's AI leadership and upcoming earnings, offering amplified returns but with significant volatility risk from daily reset leverage. Key risks include NVDA's valuation sensitivity and leverage decay during choppy markets, requiring careful risk management for investors seeking aggressive NVDA exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →
